Harmony Biosciences Reports First Quarter 2021 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Harmony Biosciences (HRMY) Tops Q1 EPS by 16c, Revenues Beat
May 11, 2021 8:04 AM EDTHarmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $59.7 million versus the consensus estimate of $57.07 million.
First Quarter 2021 Highlights:
Net product revenue of $59.7 million for the quarter ended March 31, 2021;Significant growth in WAKIX sales, supported by the addition of the cataplexy indication, which strengthens the overall... More